Research Topics
| W M ClarkSummaryAffiliation: Oregon Health and Science University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigatorsW M Clark
Oregon Stroke Center, Portland, OR 97201, USA
Stroke 31:811-6. 2000..We report here the results of the original study (part A), focusing on evaluating the safety and efficacy of rtPA given between 0 and 6 hours after stroke onset...- Potential of anticytokine therapies in central nervous system ischaemiaW M Clark
Oregon Stroke Center, Dept of Neurology UHS44, Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97201, USA
Expert Opin Biol Ther 1:227-37. 2001..Although there are no current clinical 'anti-cytokine' treatment studies for stroke, experimental studies modulating IL-1 and TNF-alpha have shown neuroprotection... - A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patientsW M Clark
Oregon Stroke Center, Oregon Health Sciences University, Portland, OR 97201, USA
Neurology 57:1595-602. 2001..Previous safety and efficacy trials in patients who have had acute strokes suggested that citicoline may improve neurologic outcome with minimal side effects... - Efficacy of antioxidant therapies in transient focal ischemia in miceW M Clark
Oregon Stroke Center, Department of Neurology, Oregon Health Sciences University, Portland, Oregon, USA
Stroke 32:1000-4. 2001..In this study we investigated the neuroprotective efficacy of EGb and LA in a clinically relevant, transient focal central nervous system ischemic model... - Cervene (Nalmefene) in acute ischemic stroke : final results of a phase III efficacy study. The Cervene Stroke Study InvestigatorsW M Clark
Oregon Stroke Center, Portland, OR 97201, USA
Stroke 31:1234-9. 2000..Results from an earlier phase II study in patients with acute ischemic stroke suggested that nalmefene was safe and tolerable and may be effective for patients <70 years old... - Efficacy of citicoline as an acute stroke treatmentWayne M Clark
Department of Neurology CR131, Oregon Health Sciences University, Oregon Stroke Center, Portland, OR97201, USA
Expert Opin Pharmacother 10:839-46. 2009..Citicoline clinical efficacy trials are now continuing outside of the US in both ischemic and hemorrhagic stroke. A citicoline supplement is now available from several sources on the internet... - Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic StrokeW M Clark
Oregon Stroke Center, Portland 97201, USA
JAMA 282:2019-26. 1999..This restricts the number of patients who can be treated, since most stroke patients present more than 3 hours after symptom onset... - A randomized efficacy trial of citicoline in patients with acute ischemic strokeW M Clark
Oregon Stroke Center, Oregon Health Sciences University, Portland 97201, USA
Stroke 30:2592-7. 1999..A previous dose-comparison trial in patients with acute stroke found that 500 mg of citicoline appeared to improve neurological outcome with minimal side effects... - Medical treatment strategies: intravenous thrombolysis, neuronal protection, and anti-reperfusion injury agentsW M Clark
Department of Neurology, Oregon Stroke Center, Oregon Health Sciences University, Portland, Oregon 97201, USA
Neuroimaging Clin N Am 9:465-73. 1999..The current status of other potential stroke therapies are also reviewed, including neuroprotective trials and agents designed to limit reperfusion injury... - Citicoline treatment for experimental intracerebral hemorrhage in miceW Clark
Oregon Stroke Center, Oregon Health Sciences University, Portland, Oregon 97201
Stroke 29:2136-40. 1998..BACKGROUND and.. - Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral ThromboembolismA Furlan
Cerebrovascular Center, Department of Neurology, Cleveland Clinic Foundation, Ohio 44195, USA
JAMA 282:2003-11. 1999..Intravenous tissue-type plasminogen activator can be beneficial to some patients when given within 3 hours of stroke onset, but many patients present later after stroke onset and alternative treatments are needed... - Temporal modulation of cytokine expression following focal cerebral ischemia in miceJ K Hill
Department of Molecular Microbiology and Immunology, Oregon Health Sciences University, Mail Code L220, 3181 Sam Jackson Park Road, Portland, OR 97201, USA
Brain Res 820:45-54. 1999.... - Doxycycline treatment reduces ischemic brain damage in transient middle cerebral artery occlusion in the ratW M Clark
Department of Neurology, Oregon Health Sciences University, Portland, USA
J Mol Neurosci 9:103-8. 1997..5 +/- 0.2 (mean +/- SE) vs control 1.3 +/- 0.3 (p = 0.03). Infarct volume: doxycycline 56 +/- 18 mm3 vs control 158 +/- 44 mm3 (p = 0.03); This protective effect supports the role of doxycycline in reducing CNS reperfusion injury... - Time course of ICAM-1 expression and leukocyte subset infiltration in rat forebrain ischemiaW M Clark
Department of Neurology, Oregon Health Sciences University, Portland 97201, USA
Mol Chem Neuropathol 26:213-30. 1995..At 4 and 7 d: only M phi accumulation, cellular morphology now similar to microglia. The results of this study indicate that early and persistent ICAM-1 expression occurs following CNS ischemia with associated leukocyte infiltration... - Current status of neuroprotective agents in the treatment of acute ischemic strokeH L Lutsep
Oregon Stroke Center, Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, CR 131, Portland, OR 97201, USA
Curr Neurol Neurosci Rep 1:13-8. 2001..Ongoing clinical trials with novel agents are trying to enroll a more homogeneous population of stroke patients in an effort to demonstrate treatment benefit... - Association of intracranial stenosis with cortical symptoms or signsH L Lutsep
Oregon Stroke Center, Oregon Health Sciences University, Portland 97201, USA
Neurology 55:716-8. 2000..Fifteen percent (5/33) of patients with cortical symptoms or signs had symptomatic intracranial stenosis of 50% or more by MR angiography or angiography, compared with 0% (0/15) of those without such findings (p < 0.005)... - Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatmentW M Clark
Department of Neurology, Oregon Health Sciences University, Portland 97201
Stroke 22:877-83. 1991..This protective effect supports the active role of leukocytes in central nervous system reperfusion ischemic injury and offers potential for future therapy... 
Drug eluting stents for symptomatic intracranial and vertebral artery stenosisJ D Fields
Interventional Neuroradiology, Department of Neurology Oregon Health and Science University, Portland, USA
Interv Neuroradiol 17:241-7. 2011....
Research Grants
- Evaluation of Antioxidant Suppl in Focal CNS IschemiaWayne Clark; Fiscal Year: 2003..The information obtained from this project will be critical in planning future clinical stroke trials involving these agents. ..